ReviewSurgical oncology clinics of North America2017
Novel Targeted Therapies for Esophagogastric Cancer.
Review in Surgical oncology clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Synthesis, preclinical evaluation and pilot clinical translation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of theACS pharmacology & translational science · 2024Article
- Review
- Claudin18.2 in Advanced Gastric Cancer.Cancers · 2023Review
- Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.Biomarker research · 2022Review
- Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer.Journal of gastrointestinal cancer · 2022Article
- Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence.Cancers · 2021Review
- Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients.PloS one · 2021Article
- CDK11Cell cycle (Georgetown, Tex.) · 2019Article
- Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.Journal of gastroenterology · 2019Review
- Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making?World journal of gastrointestinal oncology · 2018Review
- Targeted Therapies for Targeted Populations: Anti-EGFR Treatment forCancer discovery · 2018Article
- Trends in esophageal and esophagogastric junction cancer research from 2007 to 2016: A bibliometric analysis.Medicine · 2017Review
- Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.American journal of cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) is increasing in incidence. GEC, including GC and EGJ, is treated uniformly in the metastatic setting. Overall survival in the metastatic setting remains poor. Molecular characterization of GEC has identified mutations and copy number variations, along with other oncogenes, biomarkers, and immuno-oncologic checkpoints that may serve as actionable therapeutic targets. This article reviews these key aberrations, their impact on protein expression, therapeutic implications, and clinical directions within each pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.